Will alpha-fetoprotein (AFP) levels be elevated in liver cirrhosis?

Alpha-fetoprotein (AFP) is an important tumor marker commonly measured in clinical practice. AFP levels are naturally high in fetuses, peaking between the 4th and 6th months of gestation, then gradually declining after birth to reach normal adult levels within one year. So, does AFP increase in patients with liver cirrhosis?

Does AFP increase in liver cirrhosis?

AFP levels may rise in patients with liver cirrhosis, necessitating close monitoring. Currently, patients with long-standing cirrhosis face an elevated risk of developing hepatocellular carcinoma (HCC). Elevated AFP serves as a critical serum biomarker for monitoring HCC risk and evaluating therapeutic response. AFP is closely associated with the development and progression of HCC and various other malignancies, and its concentration is often elevated in multiple tumor types. While elevated AFP is frequently observed in primary liver cancer, it may also be caused by testicular cancer, ovarian cancer, malignant teratoma, or gastrointestinal tumors.

In patients with chronic liver disease—particularly those with hepatitis, including benign conditions such as hepatitis B and cirrhosis—AFP levels may also increase to varying degrees. However, these elevations are typically lower than those seen in HCC and correlate closely with the severity of hepatocyte injury. In benign liver disease, AFP elevation is usually transient, decreasing within approximately two weeks; in contrast, AFP levels in patients with malignant tumors tend to continue rising.

In daily life, maintain a regular, balanced diet—avoid spicy, irritating foods, overeating, binge eating, and late-night activities. We hope this information is helpful to you.